Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shandong Wit Dyne Health Co.,Ltd. (000915.SZ)
CNY25.75
+0.76 (+3.04%)
CN SHZ Healthcare Drug Manufacturers - Specialty & Generic
Address
Walter Plaza 250061
Jinan, CN
Jinan, CN
CEO
Jie Yang
Website
sd-wit.com
IPO
1999-06-09
ISIN CNE000000Z28
Description
Shandong Wit Dyne Health Co., Ltd., founded on June 26, 1993, and headquartered in Jinan, China, dedicates its operations to the investigation, creation, and manufacture of pharmaceuticals and health solutions tailored for children. The company offers a wide array of products, which include vitamin A and D drops, effervescent granules containing compound calcium carbonate, licorice zinc granules, iron dextran granules, and pediatric ibuprofen suppositories. Its offerings further extend to specialized medications such as azithromycin granules, dimercaptosuccinic acid capsules, rifaximin dry suspension, and oral rehydration salt powder.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY25.75
+0.76 (+3.04%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
-0.04
Float Shares
160.47M
Free Float %
68.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.25% | -2.53% | -4.61% | -15.29% | -19.77% | -17.31% | -9.78% | -28.29% | -8.60% | +11.60% | +553.59% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
25.75
DCF (Unlevered)
72.98
+183.4%
DCF (Levered)
152.40
+491.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
12.43
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
7 / 10
Strong MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+4.4% Q1'26: -33.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+3.6% Q1'26: -39.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+53.7% ★ Q1'26: +0.9% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+53.6% ★ Q1'26: +56.4% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+93.5% ★ Q1'26: +61.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.1% Q1'26: +0.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.00× ★ Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.23B
est: 1.23B (0.0%)
|
1.54B
est: 1.70B (-9.1%)
|
1.77B
est: 1.95B (-9.2%)
|
1.53B
est: 2.41B (-36.6%)
|
1.80B
est: 1.75B (+2.7%)
|
1.82B
est: 2.02B (-9.7%)
|
2.03B
est: 2.03B (-0.3%)
|
2.34B
est: 2.33B (+0.6%)
|
2.48B
est: 2.28B (+9.0%)
|
2.13B
est: 1.99B (+7.4%)
|
2.23B
est: 2.32B (-3.9%)
|
2.14B
2.14B – 2.14B
-7.6% YoY
|
2.26B
2.26B – 2.26B
+5.6% YoY
|
2.38B
2.38B – 2.38B
+5.3% YoY
|
| EBITDA |
382.37M
est: 582.81M (-34.4%)
|
464.37M
est: 803.08M (-42.2%)
|
571.58M
est: 919.92M (-37.9%)
|
347.47M
est: 1.14B (-69.5%)
|
447.48M
est: 828.60M (-46.0%)
|
629.51M
est: 952.92M (-33.9%)
|
846.14M
est: 961.42M (-12.0%)
|
1.20B
est: 1.10B (+9.3%)
|
1.33B
est: 1.08B (+23.4%)
|
1.18B
est: 1.38B (-14.4%)
|
1.26B
est: 1.60B (-21.2%)
|
1.48B
1.48B – 1.48B
-7.6% YoY
|
1.57B
1.57B – 1.57B
+5.6% YoY
|
1.65B
1.65B – 1.65B
+5.3% YoY
|
| EBIT |
345.96M
est: 542.62M (-36.2%)
|
423.83M
est: 747.69M (-43.3%)
|
528.70M
est: 856.48M (-38.3%)
|
299.49M
est: 1.06B (-71.8%)
|
390.80M
est: 771.46M (-49.3%)
|
564.09M
est: 887.20M (-36.4%)
|
776.89M
est: 895.12M (-13.2%)
|
1.13B
est: 1.02B (+10.7%)
|
1.26B
est: 1.00B (+25.2%)
|
1.10B
est: 1.32B (-16.0%)
|
1.19B
est: 1.54B (-22.3%)
|
1.42B
1.42B – 1.42B
-7.6% YoY
|
1.50B
1.50B – 1.50B
+5.6% YoY
|
1.58B
1.58B – 1.58B
+5.3% YoY
|
| Net Income |
152.46M
est: 153.24M (-0.5%)
|
198.39M
est: 229.85M (-13.7%)
|
243.20M
est: 299.98M (-18.9%)
|
129.69M
est: 400.76M (-67.6%)
|
204.10M
est: 203.89M (+0.1%)
|
290.76M
est: 311.70M (-6.7%)
|
380.26M
est: 382.01M (-0.5%)
|
526.86M
est: 546.06M (-3.5%)
|
585.26M
est: 564.81M (+3.6%)
|
515.59M
est: 474.06M (+8.8%)
|
535.08M
est: 558.55M (-4.2%)
|
506.92M
506.92M – 506.92M
-9.2% YoY
|
542.12M
542.12M – 542.12M
+6.9% YoY
|
577.33M
577.33M – 577.33M
+6.5% YoY
|
| SGA |
396.45M
est: 315.66M (+25.6%)
|
477.99M
est: 434.96M (+9.9%)
|
592.60M
est: 498.25M (+18.9%)
|
560.32M
est: 616.78M (-9.2%)
|
585.81M
est: 448.79M (+30.5%)
|
412.03M
est: 516.12M (-20.2%)
|
525.53M
est: 520.73M (+0.9%)
|
600.84M
est: 595.74M (+0.9%)
|
749.35M
est: 583.71M (+28.4%)
|
504.26M
est: 479.23M (+5.2%)
|
337.62M
est: 559.26M (-39.6%)
|
516.83M
516.83M – 516.83M
-7.6% YoY
|
545.76M
545.76M – 545.76M
+5.6% YoY
|
574.45M
574.45M – 574.45M
+5.3% YoY
|
| EPS |
0.65
est: 0.65 (0.0%)
|
0.85
est: 0.98 (-13.3%)
|
1.04
est: 1.28 (-18.8%)
|
0.55
est: 1.71 (-67.6%)
|
0.87
est: 0.87 (+0.1%)
|
1.24
est: 1.33 (-6.8%)
|
1.62
est: 1.63 (-0.6%)
|
2.25
est: 2.33 (-3.4%)
|
2.50
est: 2.41 (+3.7%)
|
2.20
est: 2.02 (+8.9%)
|
2.28
est: 2.38 (-4.2%)
|
2.16
2.16 – 2.16
-9.2% YoY
|
2.31
2.31 – 2.31
+6.9% YoY
|
2.46
2.46 – 2.46
+6.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
1.24B
OE per share TTM
5.31
Owner's Yield
19.33%
Maintenance CapEx ratio
49.51%
Maint CapEx / Avg PPE
41.1%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 22 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Emerging Markets High Dividend Fund DEM | 0.01% | 227.7K | 0.63% |
| 2 | WisdomTree Emerging Markets Equity Income UCITS ETF DEMD.L | 0.00% | 11.9K | 0.46% |
| 3 | WisdomTree Emerging Markets Equity Income UCITS ETF - Acc DEMR.L | 0.00% | 11.9K | 0.46% |
| 4 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 285.8K | 0.39% |
| 5 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 11.6K | 0.44% |
| 6 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 230.2K | 0.06% |
| 7 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 100.6K | 0.29% |
| 8 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 94.5K | 0.28% |
| 9 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 7.9K | 0.48% |
| 10 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 17.8K | 0.26% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
676.9K
Shares Outstanding
234.33M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jie Yang | MD & Director | — | female |
| Li Fu Tan | Financial Director | — | male |
| Long Jiang Wang | Deputy General Manager | — | male |
| Shuwang He | Deputy General Manager & Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 000915.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
